This article reports on a Form 4 filing for Omada Health Inc. on June 24, indicating insider transactions. The article itself is brief and primarily serves as a placeholder for the financial filing. It also includes general market data and various navigational elements from the Investing.com website.

This article announces the filing of Form 4 for Optical Cable Corporation (OCC) on June 24th. It also mentions OCC's stock performance, showing a -4.85% change. The content appears to be a very brief financial news update from Investing.com.

Passage Bio, Inc. has entered into a definitive merger agreement with Remix Therapeutics, Inc. The deal values Remix at $226 million and Passage Bio at approximately $20 million, with a planned Concurrent Financing of at least $100 million for Remix prior to closing. The combined company will be led by Remix's CEO, Peter Smith, and existing Passage Bio stockholders will receive Contingent Value Rights (CVRs) tied to future proceeds from current license agreements.

Ned S. Holmes, a director at Prosperity Bancshares Inc. (NASDAQ:PB), sold 1,100 shares of common stock totaling $79,997 on June 24, 2026, through direct and indirect transactions. The bank stock, currently trading at $72.58, is considered undervalued by InvestingPro analysis, maintains a strong dividend yield of 3.32%, and has increased its dividend for 18 consecutive years. Cantor Fitzgerald recently reiterated an "Overweight" rating with a price target of $80, despite adjusting fiscal 2026 and 2027 EPS estimates downwards.

This article from Investing.com reports on a Form 4 filing for Nextnav Acquisition Corp, dated June 24th. The brief piece indicates current market data for Nextnav and features general market information, including indices, commodities, and various stock performances.

A recent Delaware jury found Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding US$20.2 million in damages with potential trebling to US$60.61 million. This verdict highlights Amgen's exposure to intellectual property disputes concerning its antibody discovery technology, raising questions about future royalty obligations and legal risk management. While the financial impact is small relative to Amgen's scale, the focus intensifies on how these IP challenges will influence its long-term investment narrative and financial outlook amidst its current robust revenue guidance.

ServiceNow (NOW) is presented as a strong buy due to accelerating AI-driven demand and backlog growth, with its stock currently at an attractive entry point. The company is expanding its integration moat through strategic partnerships and has significantly increased its Total Addressable Market (TAM) with security and identity acquisitions. The article highlights compelling valuation metrics, including a P/E Non-GAAP of 25.33 and a FCF yield of 4.7%, alongside a probability-weighted DCF target of $181 per share.

Phil Satre, non-executive chairman of Wynn Resorts Ltd., predicts Las Vegas will continue to thrive by focusing on high-profile nongaming attractions like the Sphere and Allegiant Stadium. He highlighted that the city's success now depends on diversifying beyond gambling, with nongaming experiences accounting for a significant portion of revenue. Satre also discussed Wynn's new $3.9 billion integrated resort in the UAE and the importance of accessible pricing for Las Vegas to maintain its appeal.

U.S. Bancorp (NYSE: USB) has commented on the Federal Reserve’s Dodd-Frank Act Stress Test (DFAST) results, noting that its stress capital buffer (SCB) will remain at 2.6% until October 1, 2027, due to a Federal Reserve decision to maintain current requirements. The bank also announced a planned 3.8% increase in its quarterly common stock dividend and highlighted its strong capital levels, with a Common Equity Tier 1 (CET1) ratio of 10.8% as of March 31, 2026. CEO Gunjan Kedia affirmed the company's financial strength and resilience.

The Law Offices of Frank R. Cruz have announced a securities fraud investigation into First Solar, Inc. (NASDAQ: FSLR). This follows significant drops in the company's stock price after a downgrade by Jefferies due to lowered guidance and margin compression, and subsequent disappointing Q4 2025 financial results and conservative 2026 revenue guidance. Shareholders who incurred losses are encouraged to contact the firm to inquire about potentially pursuing a claim.